GVP Module IX: MAH and QPPV Responsibilities in Signal Management

Introduction

Signal management is a scientific process, but it is also a governance process. A signal may begin as a statistical alert or clinical observation and eventually require changes to the safety profile, risk-management measures, product information or regulatory position. The organisation therefore needs clear responsibility for ensuring that the observation is assessed, escalated and acted upon appropriately.

The marketing authorisation holder (MAH) is responsible for operating an effective pharmacovigilance system. Within that system, the qualified person responsible for pharmacovigilance (QPPV) has a defined oversight role. The QPPV is not necessarily the person who performs every signal-detection calculation or clinical assessment. The responsibility is to ensure that the pharmacovigilance system is appropriately structured, resourced and controlled, and that important safety information is recognised and managed.

Understanding the distinction between technical activity, management ownership and QPPV oversight is therefore the starting point for assessing responsibilities in signal management.

1. The MAH Owns the Pharmacovigilance System

The MAH's pharmacovigilance system provides the organisational framework within which signal management occurs. It must have appropriate processes, qualified personnel, systems, data sources and controls for identifying and evaluating emerging safety information.

Signal management cannot be treated as an isolated activity performed by a specialist team. Its effectiveness depends on interfaces with case processing, literature monitoring, aggregate reporting, risk management, medical information, regulatory affairs, clinical development and other relevant functions.

The MAH therefore needs to establish how signals are identified, who evaluates them, how significant issues are escalated and how decisions are documented and implemented.

2. The QPPV's Role Is Oversight, Not Substitution

The QPPV is responsible for the pharmacovigilance system within the scope established by EU legislation and GVP. This does not mean that the QPPV personally performs every operational task.

A mature system allows specialist functions to perform technical work while ensuring that the QPPV has sufficient visibility of important safety information and confidence that the underlying processes are effective.

For significant signals, QPPV oversight should therefore encompass the adequacy of the assessment, escalation, regulatory interfaces, resulting actions and follow-up rather than requiring the QPPV to become the sole scientific author of every assessment.

3. Responsibilities Need to Be Assigned Before a Signal Occurs

Signal management is more reliable when responsibilities are defined prospectively rather than negotiated after an important issue emerges.

The system should establish who performs detection, who validates observations, who conducts medical and statistical assessment, who owns the scientific conclusion, who determines escalation, who coordinates regulatory communication and who verifies completion of resulting actions.

These responsibilities may be distributed across functions or affiliates, but the interfaces should remain clear. A distributed operating model does not remove the MAH's overall responsibility for the pharmacovigilance system.

4. Signal Detection Responsibilities

Signal detection may use automated statistical screening, qualitative review, literature monitoring, case-series review and other information sources.

The operational team responsible for detection should understand the purpose and limitations of the methods used. Quantitative thresholds should be controlled, changes should be documented and important qualitative observations should have a defined route into the formal signal-management process.

The governance question is not simply whether a system produces alerts. It is whether the organisation can demonstrate that relevant safety information is systematically considered.

5. Validation Responsibilities

Validation requires appropriate clinical and scientific judgement. The person or function performing validation should have access to the information needed to determine whether the observation represents a potential new association or a new aspect of a known association.

The validation decision should be documented with sufficient reasoning to explain why the observation was accepted for further investigation, closed, or otherwise managed under the applicable process.

For important issues, the governance framework should provide an escalation route when the initial assessment and the potential significance of the signal do not appear proportionate.

6. Scientific Assessment Requires Appropriate Expertise

The scientific assessment of a validated signal may require several disciplines.

Clinical assessment can characterise the phenotype and evaluate alternative explanations. Epidemiological expertise may be required for comparative analyses. Statistical expertise may be needed for quantitative methods. Regulatory expertise may be needed when the conclusion could affect product information or regulatory commitments.

The MAH should therefore avoid designing signal management around a single professional discipline when the question requires multidisciplinary evidence integration.

7. The Role of Medical Judgement

Medical judgement is particularly important when interpreting individual cases, defining clinical phenotypes and determining whether observed patterns are medically plausible.

Medical review should not replace quantitative analysis where comparative evidence is needed, and statistical analysis should not replace clinical interpretation. The two functions should inform one another.

For significant signals, the organisation should be able to demonstrate that the clinical implications of the evidence were considered by appropriately qualified personnel.

8. Escalation of Important Signals

Not every signal requires escalation to the same organisational level. Escalation should be proportionate to potential patient impact, seriousness, evidence strength, urgency and possible regulatory consequences.

A potentially serious and rapidly evolving signal may require immediate senior review even when the evidence is incomplete. A low-impact issue with substantial uncertainty may remain within routine governance while additional evidence is gathered.

The escalation process should therefore be based on the decision that may be required, not simply on the numerical status assigned to the signal.

9. QPPV Visibility of Significant Safety Information

The QPPV needs appropriate visibility of significant safety information so that the QPPV can assess whether the pharmacovigilance system is functioning effectively.

This does not require every routine alert to be individually presented to the QPPV. A mature system defines criteria for significant issues, escalation and reporting so that the QPPV receives the information necessary for oversight without becoming a bottleneck for routine processing.

The criteria should reflect the significance and potential consequences of the safety issue.

10. Regulatory Communication

A signal may create regulatory obligations or require communication with competent authorities. The MAH should have a controlled process for determining when and how such communication occurs.

Regulatory communication should be based on the current scientific assessment and applicable legal or procedural requirements. It should not be delayed simply because the organisation would prefer to complete every internal analysis first when a regulatory timeline already applies.

Conversely, preliminary scientific uncertainty should not be represented as an established causal conclusion.

11. Relationship With the RMP

Signal-management conclusions can affect the risk-management system. A new or changed safety concern may require reassessment of the safety specification, additional pharmacovigilance activities or risk-minimisation measures.

The signal-management process should therefore provide a controlled interface with the RMP process. The RMP team should receive relevant conclusions and the rationale supporting them, while signal assessors should understand the existing risk-management context.

This interface is particularly important for signals concerning known risks or missing information.

12. Relationship With the PSUR

Relevant signal conclusions may need to be incorporated into periodic aggregate safety evaluation.

The PSUR process may also generate new signals or modify the understanding of an existing issue. Signal management and aggregate reporting should therefore operate as connected processes rather than independent reporting streams.

The organisation should be able to trace important signal conclusions into subsequent aggregate safety assessments where relevant.

13. Documentation and Traceability

Signal-management records should preserve the reasoning behind significant decisions.

At minimum, the organisation should be able to reconstruct the observation, validation decision, assessment performed, evidence considered, scientific conclusion, escalation, resulting action and follow-up.

The objective is not to produce a document for every routine alert. It is to ensure that significant safety decisions remain understandable and defensible after personnel, systems or organisational structures change.

14. Vendor and Affiliate Responsibilities

MAHs frequently use affiliates, service providers or other external organisations to perform elements of signal management.

Delegation of an operational task does not eliminate the MAH's responsibility for the pharmacovigilance system. Agreements should therefore define responsibilities, communication routes, escalation requirements, access to records and oversight mechanisms.

The MAH should be able to obtain the information required to evaluate significant signals even when the underlying work was performed externally.

15. Oversight of Outsourced Activities

Oversight should focus on whether the outsourced process is effective, not merely whether a contract exists.

Useful controls can include qualification, procedural requirements, performance monitoring, quality review, escalation arrangements, audit where appropriate and periodic evaluation of whether the service remains suitable for the pharmacovigilance activity performed.

For signal management, particular attention should be paid to whether potentially important observations can move reliably from the vendor into the MAH's controlled safety process.

16. Governance of Scientific Disagreement

Signal assessments can involve legitimate scientific disagreement. The governance system should provide a way to resolve or document such disagreement rather than allowing it to remain hidden in informal communications.

For significant issues, the final record should identify the principal interpretation adopted, the evidence supporting it and any material unresolved uncertainty.

The purpose is not to force unanimity. It is to ensure that the decision is controlled and reproducible.

17. QPPV Challenge

Appropriate QPPV oversight includes the ability to challenge the adequacy of the process when warranted.

The QPPV may ask whether the signal was detected appropriately, whether validation was sufficiently reasoned, whether contradictory evidence was considered, whether escalation was timely, whether regulatory obligations were identified and whether resulting actions were implemented.

This is governance challenge, not duplication of the scientific assessment.

18. A Responsibility Model

The roles can be understood as a connected chain:

MAH
 │
 ├── Pharmacovigilance system
 │       │
 │       ├── Signal detection
 │       ├── Validation
 │       ├── Scientific assessment
 │       ├── Escalation
 │       ├── Regulatory interface
 │       └── Follow-up
 │
 └── QPPV oversight
          │
          ├── System adequacy
          ├── Significant safety visibility
          ├── Challenge and escalation
          ├── Regulatory readiness
          └── Effectiveness assurance

The diagram is intentionally not a hierarchy of every individual task. It shows the distinction between the system operated by the MAH and the oversight responsibility of the QPPV.

19. Illustrative Failure Mode: The QPPV Learns About a Major Signal Late

A major signal has been under assessment for several weeks, but the QPPV is informed only after the conclusion has effectively been finalised.

The potential weakness is not necessarily that the QPPV should have performed the assessment. It is that the governance criteria did not provide timely visibility of a potentially significant safety issue.

A mature system defines escalation criteria that allow appropriate QPPV involvement before important decisions are irreversible.

20. Illustrative Failure Mode: Outsourcing Creates a Governance Gap

A service provider performs signal detection and identifies an important alert, but the contractual process does not specify how urgent signals must be escalated to the MAH.

The technical detection system may work correctly while the pharmacovigilance system as a whole fails.

This illustrates why signal management must be assessed as an end-to-end process rather than as an isolated vendor activity.

21. Illustrative Failure Mode: Responsibility Is Shared but Not Owned

A signal moves between safety surveillance, medical, epidemiology and regulatory functions. Each team assumes another team owns the final decision, and the assessment remains unresolved.

The potential weakness is an unclear accountability model. Multidisciplinary assessment requires collaboration, but a named owner should remain responsible for moving the issue through the defined process.

22. What Effective Governance Looks Like

An effective signal-management system should allow the organisation to answer five questions at any time:

1. What safety issue is being assessed?
2. Who owns the current assessment?
3. What evidence has been considered?
4. What decision or action is currently required?
5. Who provides QPPV oversight and how is completion verified?

These questions provide a compact test of whether the process is controlled without turning the system into unnecessary bureaucracy.

23. Responsibility Does Not End With the Scientific Conclusion

The conclusion of a signal assessment is the point at which governance becomes particularly important. The organisation must translate the scientific assessment into the appropriate pharmacovigilance, regulatory and risk-management response.

That response may be relatively simple, such as continued routine monitoring, or may require coordinated changes to several processes. The responsibility model should make clear who determines the action, who implements it and who verifies that it has been completed.

The QPPV's oversight is particularly relevant when the outcome has significant implications for the pharmacovigilance system or the benefit-risk profile.

24. Action Tracking

Actions resulting from signal assessment should have defined owners and, where appropriate, target dates and completion criteria.

An action should not be considered complete merely because an instruction was sent to another function. The organisation should be able to demonstrate implementation and, where relevant, assess whether the implementation achieved its intended result.

This is particularly important when a signal leads to multiple linked activities, such as regulatory submission, product-information changes, RMP updates, additional monitoring and communication.

25. Regulatory Commitments

Where signal management results in a formal regulatory commitment, the commitment should enter the appropriate controlled tracking process.

The responsible function should understand the applicable requirement, deadline, evidence needed for completion and escalation route if delivery is at risk.

The QPPV should have appropriate visibility where the commitment concerns pharmacovigilance activities or materially affects the pharmacovigilance system.

26. Product-Information Changes

A signal may result in consideration of changes to product information. The scientific assessment should provide the evidence and rationale for the proposed change, while the regulatory process determines the applicable submission and approval pathway.

The signal-management team should not assume that identifying a potential risk automatically determines the precise wording required. Product-information decisions involve regulatory and scientific assessment and may require interaction with competent authorities.

The completed change should nevertheless be traceable back to the safety issue that prompted it.

27. Risk-Minimisation Changes

Where a signal changes the understanding of a risk, existing risk-minimisation measures may need reassessment.

Possible outcomes include no change, modification of an existing measure, introduction of an additional measure or generation of evidence about effectiveness.

The decision should be proportionate to the evidence and clinical significance. A new measure should have a defined objective so that its effectiveness can subsequently be assessed where appropriate.

28. Communication Responsibilities

Some safety issues require communication beyond the immediate pharmacovigilance team.

The communication strategy should reflect the scientific certainty, potential patient impact and applicable regulatory requirements. Internal communication should ensure that affected functions understand the issue and their responsibilities. External communication may be subject to regulatory requirements and agreed processes.

Communications should not overstate the evidence. A potential signal should not be described as a confirmed adverse reaction simply because action is being considered.

29. Safety Data Exchange Within the Organisation

Signal management depends on timely access to relevant information from other pharmacovigilance processes.

Important cases, literature findings, study results and aggregate conclusions should be available to signal assessors in a controlled manner. Likewise, signal conclusions should be communicated to functions responsible for case processing, aggregate reporting, RMP management and regulatory activities.

The quality of the signal process therefore depends partly on the quality of its interfaces.

30. Management of Urgent Safety Issues

Some signals may require accelerated assessment because of potential seriousness or rapid evolution.

The MAH should have an established escalation pathway for such circumstances. The pathway should identify who can convene the appropriate experts, who can make interim decisions, how the QPPV is involved and how regulatory communication is coordinated.

Urgency does not remove the need for evidence-based reasoning. It changes the speed at which the organisation must manage uncertainty.

31. Signal Management Across Affiliates

Global MAHs may receive safety information through multiple affiliates and regional systems.

The central pharmacovigilance system should establish how relevant signals identified locally enter the global assessment process and how significant global conclusions are communicated back to affiliates.

Local regulatory requirements may differ, but the organisation should avoid allowing geographic boundaries to create blind spots in the overall safety assessment.

32. Signal Management and Data Quality

A signal-management decision is only as reliable as the information available to the assessor.

Data-quality controls therefore form part of signal governance. Important case information should be sufficiently complete and accurately coded for the analytical methods being used. Changes to coding conventions, database configuration or data extraction should be controlled because they can affect apparent signal patterns.

The assessment should distinguish a genuine change in safety information from a change caused by the data-processing environment.

33. System Changes Can Affect Signal Detection

Changes in safety databases, MedDRA versions, data sources, exposure estimates, statistical methods or screening parameters can alter the output of signal-detection systems.

A mature organisation evaluates significant methodological changes before interpreting apparent changes in signal volume as changes in product safety.

Where a system change is capable of affecting longitudinal comparability, the change and its potential impact should be documented.

34. Signal Governance and Quality Management

Signal management is part of the pharmacovigilance quality system. Procedures should be controlled, personnel appropriately qualified, records retained and significant deviations managed.

Quality should focus on whether the process achieves its intended purpose. A procedure can be perfectly documented and still ineffective if important signals are not detected, escalated or acted upon appropriately.

This makes effectiveness assessment more meaningful than procedural compliance alone.

35. Training and Competence

Personnel involved in signal management require competence appropriate to their responsibilities.

Detection specialists need to understand the methods they use and their limitations. Clinical assessors need appropriate medical knowledge. Epidemiologists and statisticians need expertise suited to the analytical questions. Regulatory personnel need to understand the applicable pathways and interfaces.

Training records demonstrate participation, but competence should ultimately be reflected in the quality of the work performed.

36. Management of Deviations

A deviation from the signal-management process should be assessed according to its potential effect on patient safety and regulatory compliance.

Not every deviation has the same significance. A missed administrative step may have limited impact, while delayed recognition or escalation of a significant safety issue can have substantial consequences.

The investigation should therefore identify the underlying process weakness and determine whether corrective or preventive action is required.

37. CAPA After a Signal-Management Failure

When a process failure is identified, CAPA should address the underlying cause rather than merely correcting the immediate record.

For example, if important signals were repeatedly escalated late, changing one deadline may not be sufficient. The organisation may need to examine detection thresholds, workload, responsibility allocation, escalation criteria, training, system configuration and management oversight.

The objective is to reduce recurrence and demonstrate that the process has become more effective.

38. Oversight of Effectiveness

The QPPV and pharmacovigilance management should have appropriate information about whether signal-management processes are effective.

Potential indicators can include timeliness of detection and validation, overdue assessments, escalation performance, quality-review results, recurring deviations and the outcome of audits or inspections.

Metrics should be interpreted carefully. A low number of validated signals does not necessarily demonstrate an effective system, and a high number does not necessarily demonstrate poor performance.

The purpose of metrics is to identify meaningful process behaviour and support management decisions.

39. Illustrative Failure Mode: Metrics Become the Objective

A team is measured primarily on how quickly signals are closed. Staff begin closing low-information observations rapidly to improve the metric, while complex assessments remain difficult to resolve.

The potential weakness is a metric that rewards administrative throughput rather than effective safety management.

A mature system balances timeliness with scientific quality, appropriate escalation and decision traceability.

40. Illustrative Failure Mode: Regulatory Action Is Tracked but Not Verified

A regulatory requirement is marked complete when the submission is sent, although the organisation has not confirmed that the approved change was implemented in all relevant systems and documents.

The potential weakness is confusing initiation of an action with completion of the resulting control.

41. Illustrative Failure Mode: The QPPV Receives Metrics but Not Context

A dashboard reports that all signal assessments are within target timelines, but does not identify a major signal that has repeatedly changed status or required urgent escalation.

The potential weakness is providing performance data without the context necessary for effective oversight.

QPPV reporting should support understanding of significant safety issues, not simply demonstrate that numerical targets have been met.

42. Governance of No-Action Decisions

A decision not to take additional action should receive governance proportionate to the significance of the signal.

The organisation should document the evidence supporting the decision, relevant uncertainty, ongoing monitoring and circumstances that would trigger reassessment.

This provides a controlled alternative to both overreaction and premature closure.

43. Periodic Reassessment

Signal-management governance should not end when a signal is closed or an action has been implemented.

New evidence may change the scientific conclusion, and completed risk-minimisation measures may require effectiveness assessment. Aggregate reporting and routine surveillance can also identify information that reopens a previously assessed question.

The system should therefore support controlled reassessment throughout the product lifecycle.

44. QPPV Oversight as a Lifecycle Control

The QPPV's role is best understood across the complete lifecycle:

Detection
   ↓
Validation
   ↓
Assessment
   ↓
Escalation
   ↓
Decision
   ↓
Regulatory / PV action
   ↓
Implementation
   ↓
Effectiveness
   ↓
Reassessment

At each stage, the level of QPPV involvement should be proportionate to significance. The objective is not constant intervention but effective oversight of the pharmacovigilance system.

45. Governance Questions for the MAH

A mature MAH should be able to demonstrate:

• defined ownership of signal-management activities;
• appropriate scientific expertise;
• controlled escalation criteria;
• QPPV visibility of significant safety issues;
• traceable regulatory interfaces;
• documented decisions and actions;
• effective oversight of affiliates and vendors;
• controlled handling of data and system changes;
• appropriate training and competence;
• deviation and CAPA management;
• and periodic assessment of process effectiveness.

These controls describe a functioning pharmacovigilance system rather than a collection of isolated signal-management procedures.

46. Inspection Perspective: Testing the Governance Chain

An inspector evaluating signal-management governance is likely to be interested in whether the organisation can demonstrate an effective chain from information to decision and action.

The relevant evidence may be distributed across procedures, signal records, meeting records, training documentation, vendor oversight, regulatory correspondence and action tracking. The organisation should nevertheless be able to connect those records into a coherent account.

The inspection question is therefore broader than whether a signal procedure exists. It is whether the procedure is implemented effectively and whether significant safety issues receive appropriate oversight.

47. Illustrative Inspection Scenario: The Procedure and Practice Diverge

The procedure requires escalation of significant signals to the QPPV, but sampled records show that several important assessments were completed without evidence of the defined escalation.

The potential weakness is not necessarily the wording of the procedure. It is the gap between the designed control and actual operation.

The organisation should investigate whether the criteria are understood, whether the process is practical, whether responsibilities are clear and whether management oversight detects recurring deviations.

48. Illustrative Inspection Scenario: A Vendor Owns the Critical Decision

A vendor performs signal detection and validation and effectively determines which potential signals are closed, while the MAH receives only periodic summary reports.

External support can be appropriate, but the MAH must retain effective control of its pharmacovigilance system. The concern would be whether the MAH has sufficient visibility, expertise and oversight to understand and challenge significant decisions.

49. Illustrative Inspection Scenario: No Evidence of QPPV Challenge

The organisation can show that the QPPV receives a dashboard but cannot demonstrate how significant safety issues are escalated or challenged when necessary.

The potential weakness is treating QPPV oversight as passive information receipt rather than an active governance control.

The required level of challenge will vary with significance, but the system should make meaningful oversight possible.

50. The Evidence of Effective Oversight

Effective QPPV oversight is best demonstrated through the system's behaviour rather than through a statement that the QPPV is responsible.

Useful evidence can include documented escalation of significant issues, review of important signal conclusions, challenge of inadequate assessments, oversight of regulatory commitments, involvement in major deviations and evidence that recurring process weaknesses lead to corrective action.

The precise evidence will depend on the organisation's structure and the significance of the issues involved.

51. Distinguishing Governance From Micromanagement

A common design problem is to make the QPPV a mandatory approver for every signal-management decision.

Such a model may appear conservative but can reduce effectiveness by creating unnecessary bottlenecks and encouraging formal approval without meaningful review.

A stronger model uses risk-based escalation. Routine activities remain with appropriately qualified operational teams, while significant safety issues receive the level of governance necessary for their potential impact.

52. The Role of Senior Management

Signal management may require decisions that involve resources, organisational priorities or risk tolerance beyond the pharmacovigilance function.

Senior management therefore has an important role in ensuring that the pharmacovigilance system has adequate authority and resources. The QPPV should be able to escalate significant concerns through appropriate governance channels when system limitations could affect effective pharmacovigilance.

This is particularly important where workload, staffing, technology or organisational changes could impair timely signal assessment.

53. Resource Adequacy

Signal management requires sufficient qualified personnel and suitable systems to process the volume and complexity of safety information.

Resource adequacy should be assessed dynamically. A major product launch, safety issue, acquisition, database migration or regulatory change may alter workload and require additional capacity.

A system that was adequate under normal conditions may become ineffective during a significant safety event.

54. Business Continuity

Important signal-management activities should remain resilient during system outages, organisational disruption or other exceptional circumstances.

Business-continuity arrangements should identify critical activities, responsibilities, alternative communication routes and restoration priorities.

The precise arrangements are organisation-specific, but significant safety information should not become inaccessible merely because a particular system or individual is unavailable.

55. Change Management

Changes to organisational structures, vendors, procedures, databases or analytical methods can alter how signals are detected and managed.

Significant changes should therefore be assessed for their pharmacovigilance impact. Where responsibilities move between functions or organisations, the transition should preserve ownership, escalation and traceability.

Change management is especially important when a new operating model changes who has access to safety data or who can make signal decisions.

56. Periodic System Review

The effectiveness of signal management should be periodically reviewed rather than assumed from the absence of obvious failures.

Reviews can examine sampled signal records, timeliness, scientific quality, escalation, regulatory interfaces, deviations, vendor performance and action completion.

The aim is to identify whether the system continues to achieve its intended purpose as products, evidence, technology and organisational structures change.

57. A Practical QPPV Review Framework

When reviewing a significant signal, the QPPV can use a structured set of questions:

SAFETY QUESTION
      ↓
Was the signal recognised appropriately?
      ↓
Was validation scientifically adequate?
      ↓
Was the assessment proportionate to significance?
      ↓
Were important alternative explanations considered?
      ↓
Was contradictory evidence addressed?
      ↓
Is the conclusion supported by the evidence?
      ↓
Were regulatory and RMP implications assessed?
      ↓
Were actions assigned and completed?
      ↓
Is follow-up / effectiveness assured?
      ↓
Can the complete decision chain be reconstructed?

This is a governance framework, not a replacement for the detailed scientific methods used by specialist assessors.

58. A Mature MAH Operating Model

A mature operating model can be summarised as:

Distributed specialist activity
             ↓
Controlled interfaces
             ↓
Named accountability
             ↓
Risk-based escalation
             ↓
QPPV oversight
             ↓
Regulatory / PV action
             ↓
Verification of implementation
             ↓
Effectiveness and reassessment

The strength of the model lies in the interfaces. A highly capable statistical team cannot compensate for weak escalation. A strong QPPV cannot compensate for inaccessible data. A well-written procedure cannot compensate for inadequate resources.

Effective signal governance therefore depends on the system as a whole.

59. Final Principle

The MAH's responsibility is to operate an effective pharmacovigilance system capable of recognising and managing important safety information. The QPPV's responsibility is to provide appropriate oversight of that system within the legal and organisational framework.

Neither responsibility is fulfilled merely by assigning a name to a role.

The practical test is whether the organisation can demonstrate that significant safety information is detected, scientifically assessed, escalated appropriately, translated into the necessary pharmacovigilance or regulatory action, implemented effectively and revisited when new evidence emerges.

That is what turns signal management from a technical surveillance activity into a controlled component of the pharmacovigilance system.

Key Takeaways

The MAH owns the pharmacovigilance system within which signal management operates. Operational tasks may be distributed across specialist functions, affiliates and service providers, but the overall system must remain controlled and accountable.

The QPPV provides oversight rather than replacing the specialist functions that perform detection and scientific assessment. QPPV involvement should be proportionate to the significance of the safety issue and sufficient to provide meaningful challenge and assurance.

Effective governance connects detection, validation, assessment, escalation, regulatory action, implementation and follow-up. The strongest evidence of effectiveness is not a procedure or dashboard in isolation, but a traceable chain showing that the system works when significant safety information emerges.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module IX — Signal Management.
2. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module I — Pharmacovigilance systems and their quality systems.
3. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module V — Risk management systems.
4. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module VII — Periodic safety update report.
5. Regulation (EC) No 726/2004, as amended.
6. Directive 2001/83/EC, as amended.
7. Commission Implementing Regulation (EU) No 520/2012, as amended.

Regulatory Note

This article explains MAH and QPPV responsibilities in signal management within the EU pharmacovigilance framework. It distinguishes legal responsibility, operational responsibility, scientific expertise and QPPV oversight. Current legislation and GVP guidance should be verified when applying the framework to a specific organisation or product.

Inspection scenarios are illustrative and are not presented as documented regulatory findings.